Investment Thesis

. A price drop below $70 or significant negative news may warrant a reevaluation of the position.

Competitive Moat

characterized primarily by intangible assets, particularly in the realm of intellectual property and regulatory approvals. The company has established itself as a leader in transcatheter heart valve technologies, benefitting from a formidable brand reputation and extensive clinical data supporting its products. This advantage is durable over the next 5-10 years, particularly as procedural volumes for minimally invasive surgeries rise. However, competitive threats from Medtronic and Boston Scientific cannot be overlooked, as these companies are also investing heavily in similar technological advancements.

Growth Engine

Future revenue growth for Edwards Lifesciences will primarily stem from its expanding addressable market in structural heart disease, which is projected to reach approximately $10 billion by 2025. The company is well-positioned to capitalize on this growth through new product launches, including innovative solutions for mitral and tricuspid valve diseases, and geographic expansion into emerging markets. Furthermore, Edwards is gaining market share as its products are increasingly adopted in clinical settings, supported by strong physician advocacy and positive patient outcomes. The company’s pricing power remains robust, allowing for favorable margins amidst rising healthcare costs.